Substance Abuse and Psychosis

Child and Adolescent Psychiatric Clinics of North America

Volumn 22, Issue 4, 2013, Pages 643-654

  Goerke, Danielle ^a   Kumra, Sanjiv ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Adolescent psychosis; Cannabis and psychosis; Dual diagnosis; Substance induced psychosis

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; QUETIAPINE; CANNABIS;

ADOLESCENCE; ALCOHOL INTOXICATION; ANXIETY DISORDER; CANNABIS ADDICTION; COGNITIVE THERAPY; COMORBIDITY; CONCENTRATION LOSS; DISEASE SEVERITY; DSM-IV; FAMILY THERAPY; FATIGUE; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; MEDICATION COMPLIANCE; MOTIVATIONAL INTERVIEWING; PARANOID SCHIZOPHRENIA; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PATIENT REFERRAL; PERSONALIZED MEDICINE; PRIMARY PSYCHOTIC DISORDER; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOSIS; RELAPSE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; STIGMA; SUBSTANCE ABUSE; SUBSTANCE INDUCED PSYCHOTIC DISORDER; TREATMENT PLANNING; TREATMENT REFUSAL; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ADOLESCENT; ADOLESCENT DEVELOPMENT; CASE REPORT; COMPLICATION; DIFFERENTIAL DIAGNOSIS; DISEASE PREDISPOSITION; DRUG EFFECTS; MARIJUANA ABUSE; PSYCHIATRIC DIAGNOSIS; PSYCHOLOGIC TEST; PSYCHOLOGY; PSYCHOSES, SUBSTANCE-INDUCED; SECONDARY PREVENTION; YOUNG ADULT;

ADOLESCENT; ADOLESCENT DEVELOPMENT; ANTIPSYCHOTIC AGENTS; CANNABIS; DIAGNOSIS, DIFFERENTIAL; DIAGNOSIS, DUAL (PSYCHIATRY); DISEASE SUSCEPTIBILITY; HUMANS; INTERVIEW, PSYCHOLOGICAL; MARIJUANA ABUSE; PATIENT COMPLIANCE; PSYCHOSES, SUBSTANCE-INDUCED; RISK FACTORS; SECONDARY PREVENTION; YOUNG ADULT;

EID: 84883493846     PISSN: 10564993     EISSN: 15580490     Source Type: Journal    
DOI: 10.1016/j.chc.2013.06.001     Document Type: Review

References (68)

1. Lambert M., Conus P., Lubman D.I., et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand 2005, 112(2):141-148.
2. Addington J., Addington D. Effect of substance misuse in early psychosis. Br J Psychiatry Suppl 1998, 172(33):134-136.
3. Fraser S., Hides L., Philips L., et al. Differentiating first episode substance induced and primary psychotic disorders with concurrent substance use in young people. Schizophr Res 2012, 136(1-3):110-115.
4. Arendt M., Rosenberg R., Foldager L., et al. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry 2005, 187:510-515.
5. Caton C.L., Hasin D.S., Shrout P.E., et al. Stability of early-phase primary psychotic disorders with concurrent substance use and substance-induced psychosis. BrJ Psychiatry 2007, 190:105-111.
6. McGorry P.D. The influence of illness duration on syndrome clarity and stability in functional psychosis: does the diagnosis emerge and stabilise with time?. Aust N Z J Psychiatry 1994, 28(4):607-619.
7. Schwartz J.E., Fennig S., Tanenberg-Karant M., et al. Congruence of diagnoses 2years after a first-admission diagnosis of psychosis. Arch Gen Psychiatry 2000, 57(6):593-600.
8. Clark R.E., Teague G.B., Ricketts S.K., et al. Cost-effectiveness of assertive community treatment versus standard case management for persons with co-occurring severe mental illness and substance use disorders. Health Serv Res 1998, 33(5Pt 1):1285-1308.
9. Ridgely M.S., Osher F.C., Goldman H.H., et al. Executive summary: chronic mentally ill young adults with substance abuse problems: a review of research, treatment, and training issues 1987, University of Maryland School of Medicine, Mental Health Services Research Center, Baltimore (MD).
10. Jablensky A., McGrath J., Herrman H., et al. Psychotic disorders in urban areas: an overview of the study on low prevalence disorders. Aust N Z J Psychiatry 2000, 34(2):221-236.
11. McEvoy J.P., Allen T.B. Substance use (including nicotine) in schizophrenic patients. Curr Opin Psychiatry 2003, 16:199-205.
12. Akvardar Y., Tumuklu M., Akdede B.B., et al. Substance use among patients with schizophrenia in a university hospital. BCP 2004, 14(4):191-197.
13. Drake R.E., Caton C.L., Xie H., et al. Aprospective 2-year study of emergency department patients with early-phase primary psychosis or substance-induced psychosis. Am J Psychiatry 2011, 168(7):742-748.
14. Archie S., Rush B.R., Akhtar-Danesh N., et al. Substance use and abuse in first-episode psychosis: prevalence before and after early intervention. Schizophr Bull 2007, 33(6):1354-1363.
15. McCleery A., Addington J., Addington D. Substance misuse and cognitive functioning in early psychosis: a 2 year follow-up. Schizophr Res 2006, 88(1-3):187-191.
16. Wade D., Harrigan S., Edwards J., et al. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. Br J Psychiatry 2006, 189:229-234.
17. Addington J., Addington D. Impact of an early psychosis program on substance use. Psychiatr Rehabil J 2001, 25(1):60-67.
18. Hides L., Dawe S., Kavanagh D.J., et al. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br J Psychiatry 2006, 189:137-143.
19. Sorbara F., Liraud F., Assens F., et al. Substance use and the course of early psychosis: a 2-year follow-up of first-admitted subjects. Eur Psychiatry 2003, 18:133-136.
20. Strakowski S.M., Keck P.E., McElroy S.L., et al. Twelve-month outcome after a first hospitalization for affective psychosis. Arch Gen Psychiatry 1998, 55(1):49-55.
21. Eaton D.K., Kann L., Kinchen S., et al. Youth risk behavior surveillance-United States, 2007. MMWR Surveill Summ 2008, 57(4):1-131.
22. Johnston L.D., O'Malley P.M., Bachman J.G., et al. Monitoring the future national survey results on drug use, 1975-2008 2009, vol. I:1-721. Secondary School Students (NIH Publication No. 09-7402), National Institute on Drug Abuse, Bethesda (MD).
23. Andreasson S., Allebeck P., Engstrom A., et al. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987, 2(8574):1483-1486.
24. Arseneault L., Cannon M., Poulton R., et al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002, 325(7374):1212-1213.
25. van Os J., Bak M., Hanssen M., et al. Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 2002, 156(4):319-327.
26. Zammit S., Allebeck P., Andreasson S., et al. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 2002, 325(7374):1199.
27. Compton M.T., Kelley M.E., Ramsay C.E., et al. Association of pre-onset cannabis, alcohol, and tobacco use with age at onset of prodrome and age at onset of psychosis in first-episode patients. Am J Psychiatry 2009, 166(11):1251-1257.
28. Weiser M., Knobler H.Y., Noy S., et al. Clinical characteristics of adolescents later hospitalized for schizophrenia. Am J Med Genet 2002, 114(8):949-955.
29. Stefanis N.C., Delespaul P., Henquet C., et al. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004, 99(10):1333-1341.
30. Fergusson D.M., Horwood L.J., Swain-Campbell N.R. Cannabis dependence and psychotic symptoms in young people. Psychol Med 2003, 33(1):15-21.
31. Moore T.H., Zammit S., Lingford-Hughes A., et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370(9584):319-328.
32. Henquet C., Murray R., Linszen D., et al. The environment and schizophrenia: the role of cannabis use. Schizophr Bull 2005, 31(3):608-612.
33. Semple D.M., McIntosh A.M., Lawrie S.M. Cannabis as a risk factor for psychosis: systematic review. JPsychopharmacol 2005, 19(2):187-194.
34. Thomas H. Acommunity survey of adverse effects of cannabis use. Drug Alcohol Depend 1996, 42(3):201-207.
35. Fergusson D.M., Poulton R., Smith P.F., et al. Cannabis and psychosis. BMJ 2006, 332(7534):172-175.
36. Henquet C., Di Forti M., Morrison P., et al. Gene-environment interplay between cannabis and psychosis. Schizophr Bull 2008, 34(6):1111-1121.
37. Buhler B., Hambrecht M., Loffler W., et al. Precipitation and determination of the onset and course of schizophrenia by substance abuse-a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res 2002, 54(3):243-251.
38. Veen N.D., Selten J.P., van der Tweel I., et al. Cannabis use and age at onset of schizophrenia. Am J Psychiatry 2004, 161(3):501-506.
39. Mauri M.C., Volonteri L.S., De Gaspari I.F., et al. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin Pract Epidemiol Ment Health 2006, 2:4.
40. Gonzalez-Pinto A., Vega P., Ibanez B., et al. Impact of cannabis and other drugs on age at onset of psychosis. JClin Psychiatry 2008, 69(8):1210-1216.
41. Ongur D., Lin L., Cohen B.M. Clinical characteristics influencing age at onset in psychotic disorders. Compr Psychiatry 2009, 50(1):13-19.
42. Sugranyes G., Flamarique I., Parellada E., et al. Cannabis use and age of diagnosis of schizophrenia. Eur Psychiatry 2009, 24(5):282-286.
43. Foti D.J., Kotov R., Guey L.T., et al. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 2010, 167(8):987-993.
44. Barrigon M.L., Gurpegui M., Ruiz-Veguilla M., et al. Temporal relationship of first-episode non-affective psychosis with cannabis use: a clinical verification of an epidemiological hypothesis. JPsychiatr Res 2010, 44(7):413-420.
45. Pelayo-Teran J.M., Perez-Iglesias R., Mata I., et al. Catechol-O-methyltransferase (COMT) Val158Met variations and cannabis use in first-episode non-affectivepsychosis: clinical-onset implications. Psychiatry Res 2010, 179(3):291-296.
46. De Hert M., Wampers M., Jendricko T., et al. Effects of cannabis use on age at onset in schizophrenia and bipolar disorder. Schizophr Res 2011, 126(1-3):270-276.
47. Large M., Sharma S., Compton M.T., et al. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry 2011, 68(6):555-561.
48. Addington J., Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr Scand 2007, 115(4):304-309.
49. Barnes T.R., Mutsatsa S.H., Hutton S.B., et al. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry 2006, 188:237-242.
50. Caspi A., Moffitt T.E., Cannon M., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005, 57(10):1117-1127.
51. Rais M., Cahn W., Van Haren N., et al. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. Am J Psychiatry 2008, 165(4):490-496.
52. Giedd J.N., Blumenthal J., Jeffries N.O., et al. Brain development during childhood and adolescence: a longitudinal MRI study. Nat Neurosci 1999, 2(10):861-863.
53. Bartzokis G., Beckson M., Lu P.H., et al. Age-related changes in frontal and temporal lobe volumes in men: a magnetic resonance imaging study. Arch Gen Psychiatry 2001, 58(5):461-465.
54. Andersen S.L., Teicher M.H. Stress, sensitive periods and maturational events in adolescent depression. Trends Neurosci 2008, 31(4):183-191.
55. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 2000, 24(4):417-463.
56. Mato S., Del Olmo E., Pazos A. Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. Eur J Neurosci 2003, 17(9):1747-1754.
57. Rubino T., Zamberletti E., Parolaro D. Adolescent exposure to cannabis as a risk factor for psychiatric disorders. JPsychopharmacol 2012, 26(1):177-188.
58. Bossong M.G., Niesink R.J. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol 2010, 92(3):370-385.
59. Kreyenbuhl J., Nossel I.R., Dixon L.B. Disengagement from mental health treatment among individuals with schizophrenia and strategies for facilitating connections to care: a review of the literature. Schizophr Bull 2009, 35(4):696-703.
60. Conus P., Lambert M., Cotton S., et al. Rate and predictors of service disengagement in an epidemiological first-episode psychosis cohort. Schizophr Res 2010, 118(1-3):256-263.
61. Turner M.A., Boden J.M., Smith-Hamel C., et al. Outcomes for 236 patients from a 2-year early intervention in psychosis service. Acta Psychiatr Scand 2009, 120(2):129-137.
62. Miller R., Ream G., McCormack J., et al. Aprospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia. Schizophr Res 2009, 113(2-3):138-144.
63. Carr J.A., Norman R.M., Manchanda R. Substance misuse over the first 18 months of specialized intervention for first episode psychosis. Early Interv Psychiatry 2009, 3(3):221-225.
64. Levy E., Pawliuk N., Joober R., et al. Medication-adherent first-episode psychosis patients also relapse: why?. Can J Psychiatry 2012, 57(2):78-84.
65. Jackson H.J., McGorry P.D. The recognition and management of early psychosis: a preventive approach 2009, Cambridge University Press, New York. 2nd edition.
66. Caton C.L., Hasin D.S., Shrout P.E., et al. Predictors of psychosis remission in psychotic disorders that co-occur with substance use. Schizophr Bull 2006, 32(4):618-625.
67. Tucker P. Substance misuse and early psychosis. Australas Psychiatry 2009, 17(4):291-294.
68. Terry-McElrath Y.M., O'Malley P.M., Johnston L.D. Saying no to marijuana: why American youth report quitting or abstaining. JStud Alcohol Drugs 2008, 69(6):796-805.